Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling

International Journal of Pharmaceutics

Volumn 411, Issue 1-2, 2011, Pages 215-222

  Liu, Peng ^a   Rong, Xinyu ^a,b   Laru, Johanna ^c   Van Veen, Bert ^c   Kiesvaara, Juha ^c   Hirvonen, Jouni ^a   Laaksonen, Timo ^a   Peltonen, Leena ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c ORION CORPORATION   (Finland)

Author keywords

Dissolution rate; Hydrophobic drug; Nanosuspensions; Stabilizer; Wet milling

Indexed keywords

INDOMETACIN; ITRACONAZOLE; MACROGOL; NANOPARTICLE; POLOXAMER; POLYSORBATE 80;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; NANOFABRICATION; NANOSUSPENSION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ROOM TEMPERATURE; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY; WET MILLING TECHNIQUE; X RAY POWDER DIFFRACTION;

BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; INDOMETHACIN; ITRACONAZOLE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POLOXAMER; SOLUBILITY; SUSPENSIONS; WATER;

EID: 79955969698     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.03.050     Document Type: Article

References (34)

1. Cerdeira, A.M., Mazzotti, M., Gander, B., 2010. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int. J. Pharm. 396, 210-218.
2. Chaubal, M.V., Popescu, C., 2008. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm. Res. 25, 2302-2308.
3. Chingunpituk, J., 2007. Nanosuspension technology for drug delivery. Walailak J. Sci. Technol. 4, 139-153.
4. Crisp, M.T., Tucker, C.J., Rogers, T.L., Williams III, R.O., Johnston, K.P., 2007. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J. Control. Release 117, 351-359. (Pubitemid 46216578)
5. Dai, W.G., Dong, L.C., Song, Y.Q., 2007. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int. J. Pharm. 342, 201-207.
6. Date, A.A., Patravale, V.B., 2004. Current strategies for engineering drug nanoparticles. Curr. Opin. Colloid Interface Sci. 9, 222-235.
7. Dolenc, A., Kristl, J., Baumgartner, S., Planinšek, O., 2009. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 376, 204-212.
8. Hecq, J., Deleers, M., Fanara, D., Vranckx, H., Amighi, K., 2005. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299, 167-177.
9. Jacobs, C., Kayser, O., Müller, R.H., 2001. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int. J. Pharm. 214, 3-7.
10. Jacobs, C., Müller, R.H., 2002. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19, 189-194.
11. Jinno, J., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G.G., Higaki, K., Kimura, T., 2006. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111, 56-64. (Pubitemid 43289995)
12. Kassem, M.A., Abdel Rahman, A.A., Ghorab, M.M., Ahmed, M.B., Khalil, R.M., 2007. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340, 126-133.
13. Kayser, O., Olbrich, C., Yardley, V., Kiderlen, A.F., Croft, S.L., 2003. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254, 73-75.
14. Keck, C.M., Müller, R.H., 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62, 3-16.
15. Kesisoglou, F., Panmai, S.,Wu,Y.H., 2007. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644.
16. Kipp, J.E., 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284, 109-122.
17. Lee, J., 2003. Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. 92, 2057-2068.
18. Lee, J., Choi, J.Y., Park, C.H., 2008. Characteristics of polymers enabling nanocomminution of water-insoluble drugs. Int. J. Pharm. 355, 328-336.
19. Lee, M.K., Kim, S., Ahn, C.H., Lee, J., 2010. Hydrophilic and hydrophobic amino acid copolymers for nano-comminution of poorly soluble drugs. Int. J. Pharm. 384, 173-180.
20. Mishra, P.R., Shaal, L.A., Müller, R.H., Keck, C.M., 2009. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int. J. Pharm. 371, 182-189.
21. Müller, R.H., Jacobs, C., Kayser, O., 2001. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19.
22. Müller, R.H., Peters, K., 1998. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size - reduction technique. Int. J. Pharm. 160, 229-237.
23. Möschwitzer, J., Achleitner, G., Pomper, H., Müller, R.H., 2004. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 58, 615-619.
24. Peltonen, L., Hirvonen, J., 2010. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J. Pharm. Pharmacol. 62, 1569-1579.
25. Pu, X., Sun, J., Wang, Y., Wang, Y., Liu, X., Zhang, P., Tang, X., Pan, W., Han, J., He, Z., 2009. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int. J. Pharm. 379, 167-173.
26. Savolainen, M., Heinz, A., Strachan, C., Gordon, K.C., Yliruusi, J., Rades, T., Sandler, N., 2007. Screening for differences in the amorphous state of indomethacin using multivariate visualization. Eur. J. Pharm. Sci. 30, 113-123.
27. Sepassi, S., Goodwin, D.J., Drake, A.F., Holland, S., Leonard, G., Martini, L., Lawrence, M.J., 2007. Effect of polymer molecular weight on the production of drug nanoparticles. J. Pharm. Sci. 96, 2655-2666.
28. Sharmaa, P., Denny, W.A., Garg, S., 2009. Effect of wet milling process on the solid state of indomethacin and simvastatin. Int. J. Pharm. 380, 40-48.
29. Suleiman, M.S., Najib, N.M., 1990. Kinetics of alkaline hydrolysis of indomethacin in the presence of surfactants and cosolvents. Drug Dev. Ind. Pharm. 16, 695-706.
30. Teeranachaideekul, V., Junyaprasert, V.B., Souto, E.B., Müller, R.H., 2008. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int. J. Pharm. 354, 227-234.
31. Van Eerdenbrugh, B., Van den Mooter, G., Augustijns, P., 2008. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 364, 64-75.
32. Van Eerdenbrugh, B., Vermant, J., Martens, J.A., Froyen, L., Van Humbeeck, J., Augustijns, P., Van den Mooter, G., 2009.Ascreening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. 98, 2091-2103.
33. Wong, J., Brugger, A., Khare, A., Chaubal, M., Papadopoulos, P., Rabinow, B., Kipp, J., Ning, J., 2008. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 60, 939-954.
34. Xiong, R., Lu, W., Li, J., Wang, P., Xu, R., Chen, T., 2008. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int. J. Pharm. 350, 338-343.